Liver enzyme elevation in hepatitis C virus (HCV) - HIV-coinfected patients prior to and after initiating HAART: Role of HCV genotypes

AIDS Research and Human Retroviruses

Volumn 22, Issue 2, 2006, Pages 139-143

  Maida, Ivana ^a   Babudieri, Sergio ^a   Selva, Cinzia ^b   D'Offizi, Gianpiero ^b   Fenu, Luisa ^a   Solinas, Giuliana ^a   Narciso, Pasqualino ^b   Mura, Maria Stella ^a   Núnez, Marina ^c  

^a UNIVERSITY OF SASSARI   (Italy)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS C VIRUS RNA; INDINAVIR; LIVER ENZYME; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; UNCLASSIFIED DRUG; VIRUS RNA;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CD4 LYMPHOCYTE COUNT; CELLULAR IMMUNITY; FEMALE; GENOTYPE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INCIDENCE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR;

ADULT; ALANINE TRANSAMINASE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED;

EID: 33244484852     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.22.139     Document Type: Article

References (31)

1. Rodríguez-Rosado R, García-Samaniego J, and Soriano V: Hepatotoxicity after introduction of highly active antiretroviral therapy. AIDS 1998;12:1256.
2. Saves M, Vandentorren S, Daucourt V, et al.: Severe hepatic cytolysis: Incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. AIDS 1999;13:F115-F121.
3. Sulkowski M, Thomas D, Chaisson R, and Moore R: Hepatotoxicity associated with antiretroviral therapy in adults infected with HIV and the role of hepatitis C or B virus infection. JAMA 2000;283:74-80.
4. Den Brinker M, Wit F, Wertheim-van Dillen P, et al.: Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000;14:2895-2902.
5. Saves M, Raffi F, Clevenbergh P, et al.: Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in HIV-infected patients. Antimicrob Agents Chemother 2000;44:3451-3455.
6. Núñez M, Lana R, Mendoza J, Martín-Carbonero L, and Soriano V: Risk factors for severe hepatic injury following the introduction of HAART. J Acquir Immune Defic Syndr 2001;27:426-431.
7. Bonfanti P, Landonio S, Ricci E, et al.: Risk factors for hepatotoxicity in patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001;27:316-318.
8. D'Arminio Monforte A, Bugarini R, Pezzotti P, et al.: Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART. J Acquir Immune Defic Syndr 2001;28:114-123.
9. Aceti A, Pasquazzi C, Zechini B, De Bac C, and The LIVER-HAART Group: Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV. The role of hepatitis B and C virus infection. J Acquir Immune Defic Syndr 2002;29:41-48.
10. Wit F, Weverling G, Weel J, Jurrians S, and Lange J: Incidence and risk factors for severe hepatotoxicity associated with anti-retroviral combination therapy. J Infect Dis 2002;186:23-31.
11. John M, Flexman J, and French A: Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: An immune restoration disease? AIDS 1998;12:2289-2293.
12. Vento S, Garofano T, Renzini C, et al.: Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral combination therapy. AIDS 1998;12:116-117.
13. Sulkowski M, Thomas D, Mehta S, Chaisson R, and Moore R: Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: Role of hepatitis C and B infections. Hepatology 2002;35:182-189.
14. Cooper C and Cameron D: Review of the effect of highly active antiretroviral therapy on HCV RNA levels in HIV and HCV coinfection. Clin Infect Dis 2002;35:873-879.
15. Núñez M and Soriano V: Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. Drug Safety 2005;28:53-66.
16. Núñez M, Ríos P, Martín-Carbonero L, Pérez-Olmeda M, González-Lahoz J, and Soriano V: Role of hepatitis C virus genotype in the development of severe transaminase elevation after the introduction of antiretroviral therapy. J Acquir Immune Defic Syndr 2002;30:65-68.
17. Stark K, Schreier E, Muller R, Wirth D, Driesel G, and Bienzle U: Prevalence and determinants of anti-HCV seropositivity and of HCV genotype among intravenous drug users in Berlin. Scand J Infect Dis 1995;27:331-337.
18. Vitale F, Villafrate M, Viviano E, et al.: Distribution of hepatitis C virus genotypes among intravenous drug users. A ten-year study in Palermo, Sicily. New Microbiol 1998;21:335-342.
19. Franchini M, Rossetti G, Tagliaferri A, et al.: The natural history of chronic hepatitis C in a cohort of HIV-negative Italian patients with hereditary bleeding disorders. Blood 2001;98:1836-1841.
20. Pérez-Olmeda M, Ríos P, Núñez M, García-Samaniego J, Romero M, and Soriano V: Virological characteristics of hepatitis C virus infection in HIV-infected individuals with chronic hepatitis C: Implications for treatment. AIDS 2002;16:493-495.
21. Bonacini M, Govindarajan S, Black L, Schmid P, Conrad A, and Lindsay K: Patients co-infected with human immunodeficiency virus and hepatitis C virus demonstrate higher levels of hepatic HCV RNA. J Viral Hepat 1999;6:203-208.
22. Rai R, Wilson L, Astemborski J, et al.: Severity and correlates of liver disease in hepatitis C virus-infected injection drug users. Hepatology 2002;35:1247-1255.
23. Sherman K, Rouster S, Chung R, and Rajicic N: Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: A cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002;34:831-837.
24. Fleming C, Craven D, Thornton D, Tumilty S, and Nunes D: Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: Low eligibility for interferon treatment. Clin Infect Dis 2003;36:97-100.
25. Martín-Carbonero L, Núñez M, González-Lahoz J, and Soriano V: Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine. HIV Clinical Trials 2003;4:115-120.
26. Harris D, Gonin R, Alter H, et al.: The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse. Ann Intern Med 2001;134:120-124.
27. Puoti M, Torti C, Ripamonti D, et al.: Severe hepatotoxicity during combination antiretroviral treatment: Incidence, liver histology, and outcome. J Acquir Immune Defic Syndr 2003;32:259-267.
28. Rutschmann O, Negro F, Hirschel B, Hadengue A, Anwar D, and Perrin L: Impact of treatment with HIV protease inhibitors on hepatitis C viremia in patients coinfected with HIV. J Infect Dis 1998;177:783-785.
29. Gavazzi G, Bouchard O, Leclercq P, et al.: Change in transaminases in hepatitis C virus- and HIV-coinfected patients after highly active antiretroviral therapy: Differences between complete and partial virologic responders? AIDS Res Hum Retroviruses 2000;16:1021-1023.
30. Chung R, Evans S, Yang Y, et al.: Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. AIDS 2002;16:1915-1923.
31. Stone S, Lee S, Keane N, Price P, and French M: Association of increased hepatitis C virus (HCV)-specific IgG and soluble CD26 dipeptidyl peptidase IV enzyme activity with hepatotoxicity after highly active antiretroviral therapy in human immunodeficiency virus-HCV-coinfected patients. J Infect Dis 2002;186:1498-1502.